AN2 Therapeutics (ANTX) Interest & Investment Income (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Interest & Investment Income of $523000.0 for Q1 2026, down 41.1% year-over-year from $888000.0 in Q1 2025, and down 13.55% quarter-over-quarter from $605000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Interest & Investment Income (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Interest & Investment Income for 5 consecutive years, with $523000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 41.1% year-over-year to $523000.0; the TTM figure through Mar 2026 stood at $2.6 million (down 45.06% YoY), while the FY2025 annual figure was $2.9 million, down 46.32% from the prior year.
- Interest & Investment Income declined to $523000.0 in Q1 2026 per ANTX's latest filing, from $605000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.7 million in Q1 2024 and bottomed at $27000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $790307.7 across 4 years, with a median of $687000.0 in 2025.
- Annual changes were most pronounced in 2022 — Interest & Investment Income soared 2233.33% — and 2025, when it tumbled 47.82%.
- AN2 Therapeutics' Interest & Investment Income stood at $630000.0 in 2022, then jumped by 70.79% to $1.1 million in 2024, then tumbled by 43.77% to $605000.0 in 2025, then dropped by 13.55% to $523000.0 in 2026.
- Business Quant data shows ANTX's Interest & Investment Income at $523000.0 in Q1 2026, $605000.0 in Q4 2025, and $687000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | 720,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 720,000.00 |
| Mar 31, 2026 | 523,000.00 |
| Dec 31, 2025 | 605,000.00 |
| Sep 30, 2025 | 687,000.00 |
| Jun 30, 2025 | 754,000.00 |
| Mar 31, 2025 | 888,000.00 |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 1.27 Mn |
| Jun 30, 2024 | 1.45 Mn |
| Mar 31, 2024 | 1.68 Mn |
| Dec 31, 2022 | 630,000.00 |
| Sep 30, 2022 | 466,000.00 |
| Jun 30, 2022 | 228,000.00 |
| Mar 31, 2022 | 27,000.00 |
| Dec 31, 2021 | 27,000.00 |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 15,000.00 |
| Mar 31, 2021 | 2,000.00 |